Neuroendocrine Tumors Drug Pipeline Analysis Report 2024

Report Coverage

The Neuroendocrine Tumors Drug Pipeline Report by Expert Market Research gives comprehensive insights into neuroendocrine tumors drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for neuroendocrine tumors. The report includes the analysis of over 50 pipeline drugs and 15+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from neuroendocrine tumors.

The detailed analysis of each drug, drug class, clinical studies, phase type, molecule type, route of administration and ongoing product development activities related to neuroendocrine tumors are covered.

Neuroendocrine Tumors Drug Pipeline Outlook

Neuroendocrine cells combine the properties of nerve cells and hormone-producing endocrine cells. Neuroendocrine tumors occur due to uncontrolled cell growth which may be because of genetic mutations. Although NETs can occur anywhere in the body, the pancreas, gastrointestinal system, and the lungs are where they most frequently do. There is a correlation between an elevated risk of developing a certain type of NETs and certain inherited genetic disorders, such as multiple endocrine neoplasia type 1 (MEN1).

Upon the detection of tumor, surgery is considered the first line of treatment to remove the entire tumor. Targeted drugs, such as everolimus and somatostatin analogs are preferred for advanced or metastatic NETs. These therapies help manage the symptoms and decrease the growth of the tumor. Radiation therapy is often used to subside symptoms in incurable tumors, while chemotherapy is often used to treat aggressive malignancies. For some types of advanced NETs, peptide receptor radionuclide treatment (PRRT) proves to be beneficial. For instance, a trial is investigating the tolerability and efficacy of a drug that could be used in unresectable and locally advanced cancer. The presence of a large number of clinical trials for neuroendocrine tumors has influenced the pipeline landscape positively.

Neuroendocrine Tumors – Drug Pipeline Therapeutic Assessment

Neuroendocrine Tumors – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for neuroendocrine tumors with around 18 pipeline drugs in phase II.

Neuroendocrine Tumors – Pipeline Assessment Segmentation, By Molecule Type

The drug molecules categories covered under neuroendocrine tumors pipeline analysis includes recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymer, and gene therapy. Several trials are ongoing to assess the efficacy of small molecules. Studies that targeted monoclonal antibodies have been highly effective in the management of neuroendocrine tumors. The report provides a comparative analysis of the molecule type for each molecule in various phases of clinical trials for neuroendocrine tumors.

Neuroendocrine Tumors Clinical Trials Assessment – Competitive Dynamics

The EMR report for the neuroendocrine tumors drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in neuroendocrine tumors clinical trials:

• Novartis Pharmaceuticals
• Provectus Biopharmaceuticals, Inc.
• Hutchmed (China) Ltd
• Camurus AB
• Wren Laboratories LLC
• TaiRx, Inc.
• ITM Solucin GmbH
• Ipsen SA
• Radiomedix, Inc.
• Sinotau Pharmaceutical Group
• Clarity Pharmaceuticals Ltd

Neuroendocrine Tumors – Pipeline Drugs Profile

Major drugs currently in the pipeline are as follows:

Drug: Lutetium Oxodotreotide

The trial compares Lutetium [177Lu] Oxodotreotide Injection to high-dose Octreotide LAR in treating advanced gastroenteropancreatic neuroendocrine tumors. The trial is sponsored by Sinotau Pharmaceutical Group and is currently under phase III.

Drug: Lutetium Edotreotide

The study evaluates 177Lu-Edotreotide PRRT versus Everolimus in treating inoperable, progressive gastroenteric...

Drug: Surufatinib

The trial evaluates the efficacy and tolerability of Surufatinib in Japanese patients. The trial is sponsored ...

Reasons To Buy This Report

The Neuroendocrine Tumors Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for neuroendocrine tumors. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within neuroendocrine tumors pipeline insights.

Key Questions Answered in the Neuroendocrine Tumors – Pipeline Assessment Report

• What is the current landscape of neuroendocrine tumors pipeline drugs?
• How many companies are developing neuroendocrine tumor drugs?
• How many phase III and phase IV drugs are currently present in neuroendocrine tumors pipeline drugs?
• Which companies/institutions are leading the neuroendocrine tumors drug development?
• What is the efficacy and safety profile of neuroendocrine tumors pipeline drugs?
• What are the opportunities and challenges present in the neuroendocrine tumors drug pipeline landscape?
• Which company is conducting major trials for neuroendocrine tumor drugs?
• What are the geographies covered for clinical trials in neuroendocrine tumors?
• What are emerging trends in neuroendocrine tumors clinical trials?

Related Reports

Neuroendocrine Tumours Treatment Market

Neuroendocrine Tumor Market

Global Clinical Trials Market